Status:
COMPLETED
Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborating Sponsors:
Bedford Research Corporation, Inc.
Conditions:
Diabetes Mellitus
Foot Ulcer
Eligibility:
All Genders
Up to 99 years
Brief Summary
The purpose of this study is to evaluate risk of cancer incidence and mortality associated with the use of REGRANEX (becaplermin) in patients with diabetes who are members of a U.S. Veterans Health Ad...
Detailed Description
This is an observational study of patients with diabetes who are eligible for care through the national Department of Veterans Affairs Health Care System (VA), representing the largest sample of older...
Eligibility Criteria
Inclusion
- Patients with diabetic foot ulcers who are members of the U.S Department of Veterans Affairs Health Care System (VA)
Exclusion
- History of cancer (including nonmelanoma skin cancer) prior to study entry
Key Trial Info
Start Date :
March 1 2010
Trial Type :
OBSERVATIONAL
End Date :
March 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01235260
Start Date
March 1 2010
End Date
March 1 2011
Last Update
July 19 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.